{"name":"Multitude Therapeutics (Australia) Pty Ltd","slug":"multitude-therapeutics-australia-pty-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"AMT-562","genericName":"AMT-562","slug":"amt-562","indication":"Other","status":"phase_1"},{"name":"AMT-253","genericName":"AMT-253","slug":"amt-253","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"AMT-562","genericName":"AMT-562","slug":"amt-562","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AMT-253","genericName":"AMT-253","slug":"amt-253","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxQQjYwcVhWSXhicmJHUHozUUpSbkgxVldVd0locFRlTEYxX0lsYWJOQ01JY1ZmZHpFejdYSmNDRmVyNnJXV2k4VWp1ZXJqYldjZ1J6OW15RVBPbGpuWUViRnZTbW91dnJST2ctQmhVSDRhRFl3NnFHU09MRllZaGFvUVNLWQ?oc=5","date":"2024-08-20","type":"deal","source":"pharmaphorum","summary":"Adcendo licenses Multitude anti-TF ADC in $1bn+ deal - pharmaphorum","headline":"Adcendo licenses Multitude anti-TF ADC in $1bn+ deal","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}